Alkermes Stock Forecast, Price & News

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALKS stock has increased by 32.1% and is now trading at $21.47.
View which stocks have been most impacted by COVID-19.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Alkermes a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alkermes wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

1,448 employees have rated Alkermes CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Alkermes' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Alkermes.

Alkermes plc (NASDAQ:ALKS) released its quarterly earnings data on Thursday, October, 29th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.40. The company had revenue of $265 million for the quarter, compared to analyst estimates of $238.39 million. Alkermes had a negative net margin of 6.28% and a positive return on equity of 9.35%. The firm's revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) EPS.
View Alkermes' earnings history.

Alkermes updated its FY20 earnings guidance on Thursday, October, 29th. The company provided EPS guidance of $0.31-0.43 for the period, compared to the Thomson Reuters consensus estimate of $0.10. The company issued revenue guidance of $1.01-1.04 billion, compared to the consensus revenue estimate of $982.45 million.

10 brokerages have issued 12-month target prices for Alkermes' shares. Their forecasts range from $15.00 to $28.00. On average, they expect Alkermes' stock price to reach $21.09 in the next twelve months. This suggests that the stock has a possible downside of 1.8%.
View analysts' price targets for Alkermes or view Wall Street analyst' top-rated stocks.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all of ALKS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by a number of retail and institutional investors. Top institutional investors include Meditor Group Ltd (0.38%), Rhenman & Partners Asset Management AB (0.13%), Diversified Trust Co (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops.
View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd, and Rhenman & Partners Asset Management AB. Company insiders that have sold Alkermes company stock in the last year include David W Anstice, Iain Michael Brown, Michael J Landine, and Richard F Pops.
View insider buying and selling activity for Alkermes or view top insider-selling stocks.

ALKS stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Pacer Advisors Inc..
View insider buying and selling activity for Alkermes or or view top insider-buying stocks.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $21.47.

Alkermes has a market capitalization of $3.42 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]